Showing results (71-80 of 3,350) with videos related to
Sort By:
Pageof 335
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.The Lancet. Oncology|October 4, 2017
Cancer patterns, trends, and transitions in Peru: a regional perspectiveMarion Piñeros, Willy Ramos, Sébastien Antoni, et al.The Lancet. Oncology|October 4, 2017
Assessment of cancer control capacity and readiness: the role of the International Atomic Energy AgencyMay Abdel-Wahab, Beatrix Lahoupe, Alfredo Polo, et al.The Lancet. Oncology|September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialDaniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.The Lancet. Oncology|December 26, 2018
Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic studyXiangchun Li, Sheng Zhang, Qiang Zhang, et al.The Lancet. Oncology|March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyYun Gong, Kai Yan, Feng Lin, et al.The Lancet. Oncology|September 2, 2006
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysisKent R Johnson, Clare Ringland, Barrie J Stokes, et al.The Lancet. Oncology|September 2, 2006
Heterogeneity of ductal carcinoma in situ and its effects on managementKefah Mokbel, Bruno CutuliThe Lancet. Oncology|January 2, 2007
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trialAnthony V D'Amico, Claus G RoehrbornPageof 335